Pipeline Review of Peritoneal Cancer – H2 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peritoneal Cancer – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer – Pipeline Review, H2 2019, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 21, 86, 53, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 8 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Peritoneal Cancer – Overview
• Peritoneal Cancer – Therapeutics Development
• Peritoneal Cancer – Therapeutics Assessment
• Peritoneal Cancer – Companies Involved in Therapeutics Development
• Peritoneal Cancer – Drug Profiles
• Peritoneal Cancer – Dormant Projects
• Peritoneal Cancer – Discontinued Products
• Peritoneal Cancer – Product Development Milestones
• Appendix

Companies Mentioned

• AB Science SA
• AbbVie Inc
• Advenchen Laboratories LLC
• AIM ImmunoTech Inc
• AiVita Biomedical Inc
• Aldeyra Therapeutics Inc
• Altor Bioscience LLC
• ALX Oncology Inc
• Anew Oncology Inc
• Apexigen Inc
• Apotex Inc
• Aravive Inc
• Arrien Pharmaceuticals LLC
• Ascend Biopharmaceuticals Ltd
• Ascenta Therapeutics Inc
• Astellas Pharma Inc
• Astex Pharmaceuticals Inc
• AstraZeneca Plc
• Atara Biotherapeutics Inc
• Bayer AG
• BeiGene Ltd
• Bio-Path Holdings Inc
• BioIntegrator Ltd
• Boehringer Ingelheim International GmbH
• Boston Biomedical Inc
• Bristol-Myers Squibb Co
• Celldex Therapeutics Inc
• Celsion Corp
• CerRx Inc
• Chipscreen Biosciences Ltd
• Clover Biopharmaceuticals
• Clovis Oncology Inc
• Context Therapeutics LLC
• Corcept Therapeutics Inc
• Cotinga Pharmaceuticals Inc
• Cristal Therapeutics BV
• CytomX Therapeutics Inc
• Daiichi Sankyo Co Ltd
• EirGenix Inc
• Eisai Co Ltd
• Eli Lilly and Co
• EpiThany Inc
• Epizyme Inc
• Esperance Pharmaceuticals Inc
• Exelixis Inc
• F. Hoffmann-La Roche Ltd
• Fate Therapeutics Inc
• Forty Seven Inc
• Gene Techno Science Co Ltd
• Genelux Corp
• Genentech Inc
• Genmab A/S
• GlaxoSmithKline Plc
• Gradalis Inc
• I-Mab Biopharma Co Ltd
• ImmunoGen Inc
• IMPACT Therapeutics Inc
• IMV Inc
• Incyte Corp
• Innate Pharma SA
• InSight Biopharmaceuticals Ltd
• Ionic Pharmaceuticals LLC
• Jiangsu Hengrui Medicine Co Ltd
• Johnson & Johnson
• Juno Therapeutics Inc
• Karyopharm Therapeutics Inc
• Kazia Therapeutics Ltd
• Kyowa Kirin Co Ltd
• Leap Therapeutics Inc
• Lidds AB
• Lipac Oncology LLC
• Lokon Pharma AB
• MabVax Therapeutics Holdings Inc
• Mateon Therapeutics Inc
• MaxCyte Inc
• Merck & Co Inc
• Merck KGaA
• Mersana Therapeutics Inc
• Millennium Pharmaceuticals Inc
• Morphotek Inc
• Morvus Technology Ltd
• MUCPharm Pty Ltd
• Mycenax Biotech Inc
• Neon Therapeutics Inc
• Neovii Pharmaceuticals AG
• NewLink Genetics Corp
• Northlake International LLC
• Novartis AG
• NuCana Plc
• Oasmia Pharmaceutical AB
• OBI Pharma Inc
• Oncoinvent AS
• Oncolix Inc
• Oncolytics Biotech Inc
• OncoMed Pharmaceuticals Inc
• OncoQuest Inc
• Oncovir Inc
• Ono Pharmaceutical Co Ltd
• Orano Med LLC
• Pfizer Inc
• Pharma Mar SA
• PharmAbcine Inc
• Plexxikon Inc
• Polaris Pharmaceuticals Inc
• Precigen Inc
• Prescient Therapeutics Ltd
• Prestige BioPharma Pte Ltd
• PsiOxus Therapeutics Ltd
• PTC Therapeutics Inc
• R-Pharm US LLC
• Regeneron Pharmaceuticals Inc
• Rgenix Inc
• Richter Gedeon Nyrt
• Rigel Pharmaceuticals Inc
• Samyang Holdings Corp
• Sanofi
• Sanofi Pasteur SA
• SELLAS Life Sciences Group Inc
• Shenzen SiBiono GeneTech Co Ltd
• Siam Bioscience Co Ltd
• Soricimed Biopharma Inc
• Sotio AS
• Sun Pharma Advanced Research Company Ltd
• Sutro Biopharma Inc
• Syndax Pharmaceuticals Inc
• Synermore Biologics Co Ltd
• Tara Immuno-Oncology Therapeutics LLC
• Targovax ASA
• Transgene SA
• Vascular Biogenics Ltd
• Verastem Inc
• Vyriad Inc
• Xcovery Holding Company LLC
• Xencor Inc
• Y-mAbs Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r3fo1w

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900